Eikon Therapeutics, Inc.

Unregistered Sale of Securities

None.

Use of Initial Public Offering Proceeds

On January 30, 2026, our Registration Statement on Form S-1, as amended (File No. 333-292633), or the Registration Statement, was declared effective in connection with our initial public offering, pursuant to which we sold an aggregate of 21,177,600 shares of our common stock at a price to the public of $18.00 per share. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC acted as joint book-running managers. The initial public offering closed on February 6, 2026. The offering terminated after the sale of all securities registered pursuant to the Registration Statement. The approximate aggregate net proceeds from the initial public offering were $348.1 million, after deducting underwriting discounts and commissions and other offering costs of $33.1 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates.

The net proceeds from our initial public offering have been invested according to our approved investment policy in a mix of money market funds and high-quality marketable securities that are being held to maturity. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus for our initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 5, 2026.